Search results for "Atrial Fibrillation"

showing 10 items of 410 documents

Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts

2019

Aims: The association between caffeinated coffee consumption and atrial fibrillation remains unclear. Recent studies suggest an inverse association only between a moderate caffeinated coffee consumption and atrial fibrillation, but others have reported no association. The aim of our study was to prospectively assess the association between caffeinated coffee consumption and atrial fibrillation in two Spanish cohorts, one of adults from a general population and another of elderly participants at high cardiovascular risk. Methods and results: We included 18,983 and 6479 participants from the 'Seguimiento Universidad de Navarra' (SUN) and 'Prevención con Dieta Mediterránea' (PREDIMED) cohorts,…

AdultInverse AssociationMediterranean dietEpidemiology030204 cardiovascular system & hematologyCoffeeCohort Studies03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsMediterranean dietCaffeineEnvironmental healthAtrial FibrillationmedicineHumansProspective Studies030212 general & internal medicineAgedProportional Hazards ModelsConsumption (economics)business.industryAtrial fibrillationCaffeinated coffeemedicine.diseasechemistryCardiology and Cardiovascular MedicinebusinessCaffeineEuropean Journal of Preventive Cardiology
researchProduct

Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Reg…

2019

Aims In recent years, stroke prevention in patients with atrial fibrillation (AF) has radically changed, with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs). Contemporary European data on AF thromboprophylaxis are needed. Methods and results We report 1-year follow-up data from the EURObservational Research Programme in Atrial Fibrillation (EORP-AF) General Long-Term Registry. Outcomes were assessed according to antithrombotic therapy. At 1-year follow-up, 9663 (88.0%) patients had available data for analysis: 586 (6.1%) were not treated with any antithrombotic; 681 (7.0%) with antiplatelets only; 4066 (42.1%) with vitamin K antagonist (VKA) only; 3167 (32.8%) with …

AdultMaleAcute coronary syndromemedicine.medical_specialtymedicine.drug_classHemorrhageOutcomes030204 cardiovascular system & hematologyLower riskRisk Assessment[SHS]Humanities and Social Sciences03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsPhysiology (medical)Internal medicineCause of DeathAntithromboticMedicineHumans030212 general & internal medicineProspective StudiesRegistriesPractice Patterns Physicians'StrokeAgedEORP-AF registryAged 80 and overAntithrombotic therapybusiness.industryProportional hazards modelAtrial fibrillationVitamin K antagonistMiddle Agedmedicine.diseaseAtrial fibrillationObservational registriesEuropeStrokeFemaleCardiology and Cardiovascular MedicinebusinessAntithrombotic therapy; Atrial fibrillation; EORP-AF registry; Observational registries; Outcomes; StrokeFibrinolytic agentFollow-Up Studies
researchProduct

Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.

2013

AdultMaleRegistrieRiskMiddle AgedPeripheral Arterial Diseaseatrial fibrillation; cardiovascular disease; peripheral vascular disease; Adult; Aged; Atrial Fibrillation; Female; Humans; Internal Medicine; Italy; Male; Middle Aged; Peripheral Arterial Disease; Prevalence; Registries; Risk; Societies Medical; Ankle Brachial Index; Cardiology and Cardiovascular MedicineItalycardiovascular diseaseperipheral vascular diseaseMedicalAtrial FibrillationInternal MedicinePrevalenceHumansFemaleAnkle Brachial IndexRegistriesSocietiesCardiology and Cardiovascular MedicineSocieties MedicalAgedHuman
researchProduct

Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.

2015

Background— In the meantime, catheter ablation is widely used for the treatment of persistent atrial fibrillation (AF). There is a paucity of data about long-term outcomes. This study evaluates (1) 5-year single and multiple procedure success and (2) prognostic factors for arrhythmia recurrences after catheter ablation of persistent AF using the stepwise approach aiming at AF termination. Methods and Results— A total of 549 patients with persistent AF underwent de novo catheter ablation using the stepwise approach (2007–2009). A total of 493 patients were included (Holter ECGs ≥every 6 months). Mean follow-up was 59±16 months with 2.1±1.1 procedures per patient. Single and multiple procedu…

AdultMaleReoperationmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCatheter ablationKaplan-Meier EstimateDisease-Free SurvivalYoung AdultSex FactorsHeart RatePredictive Value of TestsRecurrenceRisk FactorsPhysiology (medical)Internal medicineHeart rateAtrial FibrillationmedicineTachycardia SupraventricularHumans610 Medicine & healthAgedRetrospective StudiesAged 80 and overbusiness.industryAtrial fibrillationRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAtrial FlutterPredictive value of testsPersistent atrial fibrillationMultivariate AnalysisCardiologyCatheter AblationElectrocardiography AmbulatoryFemaleCardiology and Cardiovascular MedicinebusinessStepwise approachAnti-Arrhythmia AgentsAtrial flutterFollow-Up StudiesCirculation. Arrhythmia and electrophysiology
researchProduct

Leisure-time cross-country skiing and risk of atrial fibrillation and stroke:a prospective cohort study

2020

[No Abstract]

AdultMaleRiskmedicine.medical_specialtyEpidemiologyLeisure timeMEDLINEaivohalvausLeisure ActivitiesSkiingAtrial FibrillationmedicineHumansatrial fibrillationProspective StudiesProspective cohort studyStrokeFinlandCross countrybusiness.industryAtrial fibrillationleisure-timeMiddle Agedmedicine.diseaseeteisvärinähiihtostrokeStrokeEmergency medicineCardiology and Cardiovascular Medicinebusinesscross-country skiingvapaa-aika
researchProduct

A new risk score to assess atrial fibrillation risk in hypertensive patients (ESCARVAL-RISK Project.

2020

AbstractThis study aimed to assess atrial fibrillation (AF) incidence and predictive factors in hypertensive patients and to formulate an AF risk assessment score that can be used to identify the patients most likely to develop AF. This was a cohort study of patients recruited in primary healthcare centers. Patients aged 40 years or older with hypertension, free of AF and with no previous cardiovascular events were included. Patients attended annual visits according to clinical practice until the end of study or onset of AF. The association between AF incidence and explanatory variables (age, sex, body mass index, medical history and other) was analyzed. Finally, 12,206 patients were includ…

AdultMaleRiskmedicine.medical_specialtyTime FactorsCardiologylcsh:Medicine030204 cardiovascular system & hematologyRisk AssessmentArticleCohort Studies03 medical and health sciencesSex Factors0302 clinical medicineInternal medicineAtrial FibrillationmedicineHumansObesity030212 general & internal medicinelcsh:ScienceAgedHeart FailureMultidisciplinaryFramingham Risk Scorebusiness.industryIncidenceIncidence (epidemiology)lcsh:RHazard ratioAge FactorsAtrial fibrillationMiddle Agedmedicine.diseaseConfidence intervalRisk factorsResearch DesignHypertensionFemalelcsh:QbusinessRisk assessmentBody mass indexFollow-Up StudiesForecastingCohort study
researchProduct

Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: The use of fixed sub-therap…

2012

No data are available regarding the management of cancer patients requiring interruption of long-term vitamin-K antagonist (VKA) therapy. For this purpose, we tested the efficacy and safety of fixed doses of low-molecular weight heparin (LMWH) in substitution of VKA because of invasive procedures or chemotherapy-induced thrombocytopenia. In cancer patients on VKA, therapy was discontinued 5 ± 1 days before surgery or chemotherapy. Heparin was given at prophylactic dosage in patients at low risk and at fixed subtherapeutic doses (3,800 or 4,000 UI anti-FXa, b.i.d.) in those at high-risk for thrombosis. LMWH was reinitiated 12 hr after surgery and VKA the day after. In patients receiving chem…

AdultMaleRiskmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentLow molecular weight heparinAntineoplastic AgentsHemorrhagelow-molecular weight heparin (LMWH); long-term vitamin-K antagonist (VKA) therapy; cancer patientsSettore MED/15 - Malattie Del SanguePostoperative ComplicationsNeoplasmsThromboembolismAtrial FibrillationHumansThrombophiliaMedicinecancer thrombocytopenia low molecular weight heparinProspective StudiesProspective cohort studyAgedAged 80 and overChemotherapybusiness.industryIncidenceWarfarinAnticoagulantsCancerHematologyHeparinHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseThrombocytopeniaThrombosisSurgeryClinical trialHeart Valve ProsthesisAnesthesialow-molecular weight heparin (LMWH)FemaleWarfarinlong-term vitamin-K antagonist (VKA) therapycancer patientsbusinessmedicine.drugAmerican Journal of Hematology
researchProduct

Comparative Analysis of Patients with Acute Coronary and Cerebrovascular Syndromes from the National French Hospitalization Health Care System Databa…

2010

<i>Background:</i> Nationwide evaluations of the epidemiology of acute coronary syndrome (ACS) or cerebrovascular syndrome (CVS) are scarce. We aimed to analyze nationwide French data on patients referred to hospital for either ACS or CVS. <i>Methods:</i> Using the French national hospital discharge diagnosis records, all patients hospitalized between 2005 and 2008 with a diagnosis of ACS and CVS based on the ICD-10 were identified. We analyzed vascular risk factors and early outcomes in patients with a single hospitalization for ACS or CVS or for both ACV and CVS in a 2-month time window. <i>Results:</i> 1,187,643 patients were recorded. Among these, 638…

AdultMalemedicine.medical_specialtyAcute coronary syndromePediatricsAdolescentEpidemiologyHypercholesterolemiaMyocardial Infarctionfluids and secretionsRisk FactorsInternal medicineDiabetes mellitusAtrial FibrillationEpidemiologyDiabetes MellitusmedicineHumansHospital MortalityObesityRegistriesMyocardial infarctionAcute Coronary SyndromeStrokeAgedAged 80 and overInpatientsbusiness.industryAbsolute risk reductionAtrial fibrillationMiddle Agedequipment and suppliesmedicine.diseaseStrokeCerebrovascular DisordersHypertensionMyocardial infarction complicationsFemaleFranceNeurology (clinical)businessNeuroepidemiology
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

Effect of intravenous flecainide on atrial vulnerability in man.

1985

Sixteen patients were investigated by means of programmed atrial stimulation at 2 different driving rates: 100/min and 120/min. All patients had an increased atrial vulnerability at both driving rates. After the administration of intravenous flecainide (1 mg/kg bodyweight as a bolus, followed by the same amount infused over a period of 20 minutes), the increased vulnerability was abolished in 11 and 9 patients, respectively. In the remaining patients the rate of induced atrial tachyarrhythmia decreased. These findings correlate with a significant prolongation of the effective refractory period of the right atrium and a corresponding significant shortening of its relative refractory period. …

AdultMalemedicine.medical_specialtyAdolescentRefractory Period ElectrophysiologicalRefractory periodElectrocardiographyBolus (medicine)PiperidinesInternal medicinemedicineHumansPharmacology (medical)Infusions ParenteralHeart AtriaFlecainideAgedFlecainidemedicine.diagnostic_testbusiness.industryAtrial vulnerabilityEffective refractory periodAtrial fibrillationArrhythmias CardiacMiddle Agedmedicine.diseaseAtrial FlutterAnesthesiaCardiologyFemalebusinessElectrocardiographyAnti-Arrhythmia AgentsAtrial fluttermedicine.drugDrugs
researchProduct